BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23174904)

  • 1. BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia.
    Agatheeswaran S; Singh S; Biswas S; Biswas G; Chandra Pattnayak N; Chakraborty S
    Leukemia; 2013 Jul; 27(7):1578-80. PubMed ID: 23174904
    [No Abstract]   [Full Text] [Related]  

  • 2. Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells.
    Shinohara H; Kumazaki M; Minami Y; Ito Y; Sugito N; Kuranaga Y; Taniguchi K; Yamada N; Otsuki Y; Naoe T; Akao Y
    Cancer Lett; 2016 Feb; 371(1):1-11. PubMed ID: 26607903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTBP2 exon 10 inclusion is associated with the progression of CML and it is BCR-ABL1 dependent.
    Nandagopalan SR; Agatheeswaran S; Vadlamudi Y; Biswas S; Biswas G; Pattnayak NC; Chakraborty S
    Int J Biochem Cell Biol; 2019 Apr; 109():69-75. PubMed ID: 30726713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
    Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
    Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?
    Lopotová T; Záčková M; Klamová H; Moravcová J
    Leuk Res; 2011 Jul; 35(7):974-7. PubMed ID: 21511335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
    Marega M; Piazza RG; Pirola A; Redaelli S; Mogavero A; Iacobucci I; Meneghetti I; Parma M; Pogliani EM; Gambacorti-Passerini C
    Leukemia; 2010 Aug; 24(8):1445-9. PubMed ID: 20520635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of BCR-ABL transcripts after allogeneic stem cell transplantation for chronic myeloid leukemia.
    Goldman JM
    Biol Blood Marrow Transplant; 2013 May; 19(5):679-80. PubMed ID: 23467125
    [No Abstract]   [Full Text] [Related]  

  • 9. Influence of BCR/ABL fusion proteins on the course of Ph leukemias.
    Telegeev GD; Dubrovska AN; Dybkov MV; Maliuta SS
    Acta Biochim Pol; 2004; 51(3):845-9. PubMed ID: 15448745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
    Withey JM; Harvey AJ; Crompton MR
    Leuk Res; 2006 May; 30(5):553-60. PubMed ID: 16260034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p210(Bcr-Abl) desensitizes Cdc42 GTPase signaling for SDF-1alpha-directed migration in chronic myeloid leukemia cells.
    Chang YC; Tien SC; Tien HF; Zhang H; Bokoch GM; Chang ZF
    Oncogene; 2009 Nov; 28(46):4105-15. PubMed ID: 19718053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
    Sekine Y; Ikeda O; Mizushima A; Ueno Y; Muromoto R; Yoshimura A; Kanakura Y; Oritani K; Matsuda T
    Oncogene; 2012 Oct; 31(40):4384-96. PubMed ID: 22231445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells].
    Wang S; Chai YB; Liu F; Zhang XY; Jia W; Xie X; Yu WQ; Shang ZC; Jin BQ; Sun BZ
    Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(3):198-202. PubMed ID: 15854468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
    Peng Z; Luo HW; Yuan Y; Shi J; Huang SF; Li CL; Cao WX; Huang ZG; Feng WL
    Oncol Rep; 2011 May; 25(5):1381-8. PubMed ID: 21369701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL mutations in chronic myeloid leukemia.
    Ernst T; La Rosée P; Müller MC; Hochhaus A
    Hematol Oncol Clin North Am; 2011 Oct; 25(5):997-1008, v-vi. PubMed ID: 22054731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
    Withey JM; Marley SB; Kaeda J; Harvey AJ; Crompton MR; Gordon MY
    Br J Haematol; 2005 May; 129(3):377-80. PubMed ID: 15842662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The repression of apoptosis by activated abl oncogenes in chronic myelogenous leukaemia.
    Fernandes RS; Gorman AM; McGahon A; Lawlor M; McCann S; Cotter TG
    Leukemia; 1996 Jun; 10 Suppl 2():s17-21. PubMed ID: 8649049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcription-mediated amplification and hybridisation protection assay to determine BCR-ABL transcript levels in patients with chronic myeloid leukaemia.
    Langabeer SE; Gale RE; Harvey RC; Cook RW; Mackinnon S; Linch DC
    Leukemia; 2002 Mar; 16(3):393-9. PubMed ID: 11896544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear topography and expression of the BCR/ABL fusion gene and its protein level influenced by cell differentiation and RNA interference.
    Bártová E; Harnicarová A; Pacherník J; Kozubek S
    Leuk Res; 2005 Aug; 29(8):901-13. PubMed ID: 15978941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
    Liu JH; Wu SC; Chen WS; Yen CC; Yang MH; Tsai YC; Chen PM
    Biochem Biophys Res Commun; 2004 Jun; 318(3):764-72. PubMed ID: 15144904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.